Clinical Implementation and Future Perspectives

Dr. Brander asks about synthesizing comparative analyses and important limitations clinicians should understand when interpreting cross-trial comparisons, including balancing insights with other evidence forms. Dr. Shadman reiterates that indirect comparisons cannot replace head-to-head trials but provide necessary decision-making information when direct comparisons are unavailable. He views MIACs as supplemental information alongside treatment option pros and cons, emphasizing their position in evidence-based medicine hierarchy.

For detailed analysis evaluation, Dr. Shadman stresses examining investigator methodology including variable consideration, different scenario presentations, and transparency in sharing analytical approaches rather than selective result presentation. He recommends evaluating multiple scenarios and investigator methods for including different variables and effective sample sizes. The rapidly evolving field will generate additional evidence complementing or questioning current evidence, requiring ongoing evaluation of which evidence provides greater value.

Dr. Brander concludes with key takeaways, acknowledging that although clinicians are not statisticians, indirect trial comparisons occur naturally in clinical conversations. MIACs provide informed approaches addressing limitations of taking separate trials and synthesizing them clinically. She emphasizes recognizing stronger analyses with comparator arms versus those with greater limitations, encouraging clinician education about study capabilities and limitations. These analyses serve as hypothesis-generating tools for focusing trial efforts and developing new research questions beyond original study scopes.

Individual patient decision-making ultimately depends on goals and preferences, requiring understanding of individual CLL characteristics including disease markers that remain important with novel drugs. The discussion emphasizes maintaining focus on patients with unmet needs, requiring continued work on combinations and understanding how frontline treatments inform sequencing strategies to help patients achieve normal life expectancy and quality of life.